Immuneering Corporation (NASDAQ:IMRX - Get Free Report) CEO Benjamin J. Zeskind purchased 7,015 shares of Immuneering stock in a transaction dated Wednesday, July 2nd. The stock was bought at an average cost of $3.53 per share, with a total value of $24,762.95. Following the completion of the transaction, the chief executive officer owned 2,312,852 shares in the company, valued at approximately $8,164,367.56. This represents a 0.30% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
Immuneering Stock Down 5.6%
Shares of Immuneering stock traded down $0.20 during mid-day trading on Friday, reaching $3.39. 908,546 shares of the stock traded hands, compared to its average volume of 2,557,943. The business has a 50-day moving average of $2.00 and a 200 day moving average of $1.84. Immuneering Corporation has a fifty-two week low of $1.00 and a fifty-two week high of $3.87. The stock has a market capitalization of $122.01 million, a PE ratio of -1.73 and a beta of 0.38.
Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). On average, equities research analysts expect that Immuneering Corporation will post -1.86 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
IMRX has been the topic of several recent analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of Immuneering in a research note on Wednesday, June 18th. Oppenheimer reduced their price target on Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, Mizuho upped their price target on Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $13.25.
Check Out Our Latest Stock Analysis on IMRX
Institutional Investors Weigh In On Immuneering
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tang Capital Management LLC acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $27,000. Jane Street Group LLC acquired a new stake in shares of Immuneering in the first quarter valued at approximately $32,000. Marshall Wace LLP acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $47,000. First Manhattan CO. LLC. acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $71,000. Finally, XTX Topco Ltd grew its position in Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after acquiring an additional 20,871 shares during the period. Institutional investors and hedge funds own 67.65% of the company's stock.
Immuneering Company Profile
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Stories

Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.